Vanda Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Five approved products anchor a diversified portfolio, with BYSANTI and NEREUS launches driving near-term growth. Key clinical readouts for MDD and GLP-1-induced nausea could unlock major new markets, while commercial infrastructure is primed for expansion.
-
Two new drugs, NEREUS and BYSANTI, have been approved, with BYSANTI's launch and a major switch strategy from Fanapt expected to drive near-term revenue. Multiple phase III readouts and a focus on product diversification support a $750 million psychiatry revenue target by 2030.
-
Q2 2026 saw strong Fanapt growth and early NEREUS launch, offset by HETLIOZ declines from generic competition. Revenue guidance for 2026 is $240M–$290M, with operating expenses expected to moderate by late 2026 and cash resources sufficient through 2027.
-
Directors were elected through 2029, executive compensation and an equity plan amendment were approved, and PricewaterhouseCoopers LLP was ratified as auditor. No shareholder questions were submitted during the meeting.
-
Revenue guidance for 2026 was raised to $240–$290 million, driven by new launches and strong Fanapt growth. BYSANTI and NEREUS are expected to be key contributors, with multiple late-stage pipeline readouts and a focus on funding commercial and R&D initiatives.
-
Q1 2026 saw 26% Fanapt sales growth, NEREUS launch, and BYSANTI FDA approval. Revenue guidance was raised to $240M–$290M, with strong pipeline progress and continued investment in commercial infrastructure.
-
The company highlighted recent product approvals, robust late-stage pipeline progress, and a strong financial position. BYSANTI and Nereus launches are set for 2026, with significant revenue growth expected from psychiatry and consumer health portfolios.
-
The conference highlighted a robust late-stage pipeline, with imminent catalysts including Bysanti's PDUFA in February 2026 and NEREUS's commercial launch. Significant growth is expected from new indications, especially in motion sickness, GLP-1, and MDD.
Fiscal Year 2025
-
2025 saw 9% revenue growth to $216.1M, led by Fanapt's 24% sales increase and major regulatory wins, including Nereus approval. 2026 guidance projects $230–$260M revenue, with Fanapt driving growth and further investments in commercial and R&D activities.
-
The company highlighted its expanding psychiatry and neurology portfolio, with key regulatory milestones for Basanti, Hetlioz, and tradipitant expected in 2025–2026. Strong financials support ongoing investments in launches and pipeline growth, with Fanapt and Ponvory driving revenue gains.
-
Q3 2025 saw 18% revenue growth year-over-year, led by Fanapt's 31% sales increase and strong prescription gains. Strategic investments and expanded sales forces support future launches, while guidance was narrowed due to variable HETLIOZ sales and increased R&D spending.
-
Significant commercial expansion and prescription growth for Fanapt followed its 2024 bipolar approval, while HETLIOZ remains resilient despite generic competition. Three major regulatory milestones are expected by 2026, and financial guidance projects 15% revenue growth for 2025.
-
Multiple commercial and pipeline products are advancing, with key regulatory milestones expected for tradipitant, Bysanti, and imsidolumab. Significant commercial expansion, strong cash reserves, and a focus on new indications and business development support growth plans.
-
The conference highlighted a robust commercial portfolio, strong financials, and a pipeline with multiple near-term regulatory milestones. Fanapt’s growth is accelerating due to the bipolar indication, while milsaperidone is positioned for a major launch with improved economics and exclusivity. Up to six marketed products are targeted by 2026.
-
Q2 2025 saw 27% Fanapt revenue growth and strong new patient starts, offsetting Hetlioz and Ponvory declines. Net loss widened due to higher SG&A and R&D, but cash remains strong. 2025 revenue is guided at $210–$250 million, with growth expected to accelerate as new launches mature.
-
Q1 2025 revenue grew 5% year-over-year to $50M, led by Fanapt's 14% sales growth and strong prescription trends, while net loss widened due to R&D and commercial investments. 2025 revenue is guided at $210–$250M, with cash expected at $280–$320M by year-end.
Fiscal Year 2024
-
Q4 and full year 2024 saw revenue growth driven by Fanapt and PONVORY launches, offset by HETLIOZ declines from generic competition. 2025 revenue is guided at $210M–$250M, with major pipeline progress and expanded commercial investment supporting long-term growth.
-
A diversified portfolio is driving growth, with Fanapt expanding into bipolar disorder and new formulations, Ponvory relaunching with a dedicated sales force, and tradipitant advancing toward an NDA for motion sickness. Financial guidance remains strong, and new indications and legal actions aim to protect and expand the pipeline.
-
The event highlighted a robust commercial portfolio, recent acquisition of Ponvory, and a strong late-stage pipeline with multiple regulatory filings expected by year-end and early 2025. Financials remain solid with $380M in cash and revenue guidance raised for 2024.
-
Q3 2024 saw strong Fanapt growth, successful Ponvory transition, and stable HETLIOZ sales, with total revenue up 23% year-over-year. Net loss increased due to higher launch expenses, but 2024 sales and cash guidance were raised on positive commercial momentum.
-
Multiple commercial launches and regulatory filings are underway, including Fanapt for bipolar I, Hetlioz for new indications, and Ponvory for multiple sclerosis. Tradipitant advances toward FDA decisions for gastroparesis and motion sickness, while robust early-stage programs and strong cash reserves support ongoing growth.
-
Multiple product launches and regulatory filings are planned through 2025, with Fanapt, Hetlios, and Ponvory driving commercial growth. Tradipitant and motion sickness programs show strong clinical data, and financials remain robust with $390M cash and no debt.
-
Q2 2024 saw revenue growth driven by Ponvory's launch and Fanapt's label expansion, offset by HETLIOZ declines from generics. Net loss was $4.5M on $50.5M revenue, with full commercial impact from new launches expected later in 2024.
-
The event highlighted a strong commercial portfolio, robust late-stage pipeline, and significant market opportunities in bipolar disorder, multiple sclerosis, gastroparesis, and motion sickness. Strategic focus includes expanding indications, launching new products, and leveraging a solid cash position for growth.